Article · 16 Feb 2026
ArticlePublished 2016
Bioequivalence Study of Pegylated Doxorubicin Hydrochloride Liposome (PEGADRIA) and DOXILandreg; in Ovarian Cancer Patients: Physicochemical Characterization and Pre-clinical studies.
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Objective:To develop Pegylated Doxorubicin Hydrochloride Liposome (PEGADRIA) and compare its physicochemical properties, preclinical safety and efficacy, clinical pharmacokinetic and safety profiles with those of the reference product, Doxil®. Methods: PEGADRIA was prepared and the structure morphology, lamellarity, size, shape, drug loading, lipid bilayer and Peg layer thickness were determined. Safety studies were conducted in mice and rats and efficacy study was conducted in a P-388 leukemia mouse model. To evaluate the pharmacokinetic profile of PEGADRIA, a multicenter, open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose cross-over bioequivalence study was conducted with Doxil® in ovarian cancer patients whose disease had progressed or reoccurred after platinum based chemotherapy under fasting conditions. The pharmacokinetic parameters were determined based on the concentration-time profiles of doxorubicin, whereas the concentration was determines using LC-MS/MS methods. Results: PEGADRIA was similar to Doxil® in terms of general morphology, lamellarity, size, shape, drug loading, lipid bilayer and Peg layer thickness. PEGADRIA and Doxil® showed comparable survival benefit in leukemic mice. The toxicity profiles of PEGADRIA in both mice and rats were comparable to those of Doxil®. Plasma concentrations of doxorubicin from cancer patients were measured to determine the pharmacokinetics profile. The geometric mean ratios (90% confidence intervals) of PEGADRIA /Doxil® for free doxorubicin and encapsulated doxorubicin were similar. Conclusion: PEGADRIA was found to have similar physicochemical profile compared to Doxil®. In addition, it was safe and bioequivalent to Doxil® in ovarian cancer patients.
Subjects
NanotechnologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Nanomedicine & Nanotechnology.
Article · 21 Oct 2025
Green Synthesis of Chromium(III) Oxide Nanoparticles and their Evaluation against Skin Infections
Article · 19 Jun 2025
Potential of Bhasma as Nanomedicine for Disease Management: A Synopsis
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Nanomedicine & Nanotechnology
- SubjectNanotechnology
- BylineArticles whose byline prints “Ali SM”
- BylineArticles whose byline prints “Sheikh S”
- BylineArticles whose byline prints “Ahmad A”
- BylineArticles whose byline prints “Ahmad MU”
- BylineArticles whose byline prints “Chen P”
- BylineArticles whose byline prints “Paithankar M”
- BylineArticles whose byline prints “Choudhury K”
- BylineArticles whose byline prints “Makadia RD”
